Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists

IMPORTANCE: Age-related macular degeneration (ARMD) therapies aflibercept and ranibizumab are among the highest-cost Medicare Part B drugs, even though off-label use of lower-cost bevacizumab is clinically noninferior. Payments from manufacturers of these ARMD therapies to ophthalmologists are hypot...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickson, Sean R., James, Katelyn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492178/
https://www.ncbi.nlm.nih.gov/pubmed/37682553
http://dx.doi.org/10.1001/jamahealthforum.2023.2951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492178/
https://www.ncbi.nlm.nih.gov/pubmed/37682553
http://dx.doi.org/10.1001/jamahealthforum.2023.2951

Ejemplares similares